{
    "clinical_study": {
        "@rank": "43765", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients\n      with metastatic prostate cancer that has not responded to previous hormone therapy."
        }, 
        "brief_title": "Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy", 
        "completion_date": {
            "#text": "May 2000", 
            "@type": "Actual"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the objective response rate in patients with hormone refractory\n      prostate cancer treated with dolastatin 10. II. Determine the toxicity of this regimen in\n      this patient population.\n\n      OUTLINE: Patients receive dolastatin 10 IV bolus every 3 weeks. Treatment continues for a\n      minimum of 2 courses in the absence of unacceptable toxicity or disease progression.\n\n      PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Hormone refractory metastatic prostate cancer (stage D1 or D2)\n        with no greater than 3 prior endocrine manipulations PSA level increased on 3 consecutive\n        measurements at least 2 weeks apart PSA at least 10 ng/mL (not required if measurable\n        disease)\n\n        PATIENT CHARACTERISTICS: Age: Not specified Performance status: SWOG 0-2 Life expectancy:\n        At least 12 weeks Hematopoietic: Granulocyte count at least 1,500/mm3 Hemoglobin at least\n        8 g/dL Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 2 mg/dL AST no\n        greater than 2 times upper limit of normal Renal: Creatinine less than 2.0 mg/dL Other: No\n        other serious medical illness No serious infection No other prior malignancy within the\n        past 5 years except nonmelanoma skin cancer or any in situ carcinoma\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior\n        chemotherapy Endocrine therapy: See Disease Characteristics Concurrent LHRH-agonist\n        therapy allowed without antiandrogens At least 4 weeks since prior flutamide and\n        nilutamide At least 6 weeks since prior bicalutamide At least 4 weeks since other prior\n        hormone therapy including steroids Radiotherapy: At least 4 weeks since prior radiation\n        therapy and recovered No prior strontium Surgery: Recovered from prior surgery"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003626", 
            "org_study_id": "CDR0000066708", 
            "secondary_id": [
                "P30CA022453", 
                "WSU-D-1644", 
                "NCI-T98-0019"
            ]
        }, 
        "intervention": {
            "intervention_name": "dolastatin 10", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Dolastatin 10"
        }, 
        "keyword": [
            "stage IV prostate cancer", 
            "recurrent prostate cancer"
        ], 
        "lastchanged_date": "April 3, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/WSU-D-1644"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80262"
                    }, 
                    "name": "University of Colorado Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Barbara Ann Karmanos Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19111"
                    }, 
                    "name": "Fox Chase Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Evaluation of Dolastatin-10 in Patients With Hormone Refractory Prostate Cancer", 
        "overall_official": {
            "affiliation": "Barbara Ann Karmanos Cancer Institute", 
            "last_name": "Maha Hadi A. Hussain, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 1999", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003626"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "11106233", 
            "citation": "Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, Hussain M. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res. 2000 Nov;6(11):4205-8. Erratum in: Clin Cancer Res 2000 Dec;6(12):4967."
        }, 
        "source": "Barbara Ann Karmanos Cancer Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Barbara Ann Karmanos Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 1998", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }, 
    "geocoordinates": {
        "Barbara Ann Karmanos Cancer Institute": "42.331 -83.046", 
        "Fox Chase Cancer Center": "39.952 -75.164", 
        "University of Colorado Cancer Center": "39.739 -104.985"
    }
}